As expected, the EZH2 expression level was negatively correlated with EGR1 and JUN, while the expression of EGR1 was positively correlated with JUN, suggesting that EZH2/EGR1 and JUN/CEMIP might be the potential regulatory pathways in BC, especially in invasive BC, like TNBC and HER2+ BC, or EZH2, EGR1, and JUN mediate CEMIP expression directly in BC. Here, EZH2 is linked to breast cancer.